Vitiligo Statistics: Prevalence and Demographics

Vitiligo affects roughly 0.4% of the world’s population, or about 28 to 37 million people depending on how estimates are drawn and whether children and adults are counted together. That fraction sounds small, but it translates to one of the most common pigmentary disorders on the planet, and its distribution across regions, age groups, and ethnic backgrounds is far from uniform. The numbers also shift depending on whether researchers count only physician-confirmed cases or include people who have never received a formal diagnosis.

Global Prevalence Estimates

Two large-scale analyses published in recent years converge on similar figures but frame them slightly differently. A systematic review and meta-analysis covering studies from multiple continents put the overall prevalence at 0.40%, with no meaningful difference between women (0.50%) and men (0.49%).¹ A separate modelling study in The Lancet Public Health estimated the global lifetime prevalence of physician-diagnosed vitiligo at 0.36% across the general population, rising to 0.67% when restricted to adults.² An older meta-analysis of 82 community-based studies placed the pooled figure lower, at 0.2%, though hospital-based studies in the same review averaged 1.8%, a gap that reflects the difference between how many people in a community have white patches and how many people walk into a dermatology clinic with them.³

The practical takeaway is that if you surveyed a random group of a thousand adults from around the world, somewhere between two and seven of them would have vitiligo, with the exact number depending heavily on where they live and how carefully the survey looks for it.

Where Vitiligo Is Most and Least Common

Geography matters more than most people expect. West Asia consistently shows the highest prevalence, estimated at 0.77%, while East Asia reports the lowest, around 0.12%.¹ At the country level, Jordan has been reported with the highest single-country prevalence at about 1.3%, while Sweden sits near the bottom at roughly 0.19%.¹ The Lancet modelling study found somewhat different leaders when it used its own statistical approach: Romania, Poland, Nepal, and India all clustered near 0.53%, while Taiwan and China tied for the lowest estimates worldwide at about 0.22%.⁴

These geographic differences are not simply a matter of genetics. Awareness, healthcare access, and cultural attitudes toward skin conditions all influence how often people seek a diagnosis. In a large survey-based study across Europe, the United States, and Japan, the total estimated vitiligo prevalence (combining diagnosed, undiagnosed, and “signs of vitiligo”) was 1.3% overall. Europe led at 1.6%, the US came in at 1.4%, and Japan trailed at 0.5%.⁵ Those figures are notably higher than clinical-record-based estimates, which suggests many people with vitiligo never receive a formal diagnosis.

Age and Sex Patterns

Children and adolescents consistently show lower prevalence than adults. The global meta-analysis estimated 0.27% in those under 18 versus 0.70% in adults.¹ The Lancet modelling study estimated about 5.8 million children with vitiligo globally compared to 37.1 million adults.² That gap partly reflects cumulative onset over time: community-based prevalence appears to rise gradually with age.³ In other words, the older a population sample is, the more people in it will have developed vitiligo at some point in their lives.

As for sex, the global data point to essentially no difference. Both the meta-analysis and the modelling study found that men and women develop vitiligo at comparable rates.¹ Some individual datasets show minor skews in either direction. A dual-cohort study in Israel, for instance, found slightly higher prevalence in men in its occupational health cohort but slightly higher prevalence in women in its insurance claims data.⁶ The apparent contradictions between datasets likely stem from differences in who seeks medical care rather than a real biological gap. Women in many cultural contexts may be more likely to visit a dermatologist for cosmetic concerns, inflating their numbers in clinical records.

The Undiagnosed and Misdiagnosed

A substantial fraction of people with vitiligo go undiagnosed. The US prevalence study found that roughly a third of people whose vitiligo was confirmed by a clinician had never received a formal diagnosis before the study.⁷ Misdiagnosis is also common, with one US-focused analysis finding a 37% misdiagnosis rate. In Europe and Africa, the rates appear to be even higher, estimated at 45% and 56% respectively.⁸ On average, patients in the US wait about 2.4 years after symptoms appear before receiving a correct diagnosis.⁸

That same US study broke vitiligo down by subtype. Self-reported nonsegmental vitiligo, the more common form that tends to appear symmetrically on both sides of the body, had a prevalence of about 0.77%. Self-reported segmental vitiligo, which tends to stay on one side, was reported at 0.61%. But when clinicians reviewed those self-reports, the segmental figure dropped sharply to about 0.18%, suggesting many people mislabel their condition or confuse vitiligo with other causes of white patches.⁷

Rising Diagnosis Rates in the United States

Between 2013 and 2017, the annual diagnosed prevalence of vitiligo in US insurance claims rose more than five-fold, from 0.009% to 0.076%, with similar increases in incidence.⁹ A broader real-world analysis confirmed that incidence and prevalence continued to climb through 2021.¹⁰ Whether this reflects a genuine increase in new cases or simply better recognition and diagnostic coding is an open question. The arrival of new treatments, particularly topical JAK inhibitors approved by the FDA in recent years, has likely pushed more people to seek care and receive a diagnosis on the record. The sharp trajectory is probably a mix of real awareness gains and coding improvements rather than a sudden spike in disease.

Family History and Genetic Risk

Vitiligo has a strong familial component. A large Korean population-based cohort found that people with an affected first-degree relative had about five times the risk of developing vitiligo themselves. The risk was highest for twins of someone with vitiligo (roughly 25 times higher), followed by people with more than one affected first-degree relative (about 18 times higher), then siblings (about six times).¹¹ An earlier study in the US found that about 20% of vitiligo patients had at least one first-degree relative also affected, with children of patients at particularly high risk.¹²

A case-control study in Saudi Arabia reported that nearly half of vitiligo patients had a positive family history of the condition, compared to about 22% of controls. Having any family history roughly tripled the adjusted odds of having vitiligo.¹³ Despite this heritable pattern, vitiligo does not follow a simple dominant or recessive inheritance model. Dozens of genes contribute, most of them involved in immune regulation, and environment plays a substantial role in whether someone with genetic susceptibility ever develops visible patches.

Autoimmune and Thyroid Connections

Vitiligo clusters with other autoimmune conditions, and thyroid disease is the most common companion. A systematic review of 77 studies found that subclinical hypothyroidism was the most frequent thyroid disorder in vitiligo patients, with a pooled prevalence of about 6%.¹⁴ A nationwide Korean study quantified the risk more precisely: vitiligo patients had about 2.6 times the odds of Graves disease and 1.6 times the odds of Hashimoto thyroiditis compared to matched controls.¹⁵ One Indian study of 150 vitiligo patients found that 20% had autoimmune hypothyroidism, while just 2% of controls did, and 16% had diabetes compared to about 3% of controls.¹⁶ This is why dermatologists commonly recommend thyroid screening after a vitiligo diagnosis.

Cardiovascular and Metabolic Risk

Emerging evidence suggests that the systemic inflammation underlying vitiligo may reach beyond the skin. A large US-based retrospective study found that people with vitiligo had about a 28% higher risk of major adverse cardiovascular events than matched controls. Specific risks included a 21% increase in cerebral infarction and a 27% increase in venous thromboembolism.¹⁷ A separate meta-analysis found that metabolic comorbidities were common among vitiligo patients: about 43% had hyperlipidemia, roughly 38% had obesity, and about 28% met criteria for metabolic syndrome.¹⁸ These findings are still being debated, and the direction of causality is unclear. Shared inflammatory pathways may drive both vitiligo and cardiovascular risk, rather than one causing the other.

Mental Health and Quality of Life

The psychological burden of vitiligo is substantial and measurable. A meta-analysis of studies using standardized questionnaires found that about 29% of vitiligo patients met criteria for depression and about 33% for anxiety.¹⁹ A cross-sectional study found that depression prevalence scaled with how much skin was affected: about 22% of patients with less than 10% of body surface area involved were depressed, climbing to 100% in those with more than 80% involvement.²⁰

A UK cohort study tracked people with vitiligo over time and found that they developed new depression and anxiety at higher rates than matched controls. The risk was especially pronounced in Black and minority ethnic individuals, who had about 72% higher rates of recurrent depressive disorder after a vitiligo diagnosis compared to controls.²¹ This disparity likely reflects both the greater visibility of depigmentation on darker skin and the compounding effects of racial stigma.

Healthcare Access and Economic Costs

Non-Caucasian individuals with vitiligo face worse healthcare access and lower utilization of care than their Caucasian counterparts, even after accounting for the expected differences in quality of life.²² These gaps in access layer on top of the psychological burden already described and likely contribute to later diagnoses and worse outcomes in disadvantaged communities.

Vitiligo also carries a measurable financial toll. A US claims analysis found that patients with vitiligo incurred about twice the total annual healthcare costs of matched controls, with vitiligo-specific costs averaging roughly $3,500 per year.²³ A European economic analysis found that patients themselves bore about 95% of their total medical costs, with supplements and treatments each making up roughly a third and indirect costs related to mental health contributing an additional layer.²⁴ The out-of-pocket burden reflects the historical reality that many insurers treated vitiligo as purely cosmetic, though this has been gradually shifting as autoimmune mechanisms have become better understood and new prescription treatments have reached the market.

Skin Cancer Risk in People With Vitiligo

One of the more counterintuitive findings in vitiligo epidemiology is a markedly lower risk of skin cancer. A UK population-based cohort found that people with vitiligo had about a 38% reduced risk of new skin cancer overall, with melanoma risk cut by roughly 61%.²⁵ A Taiwanese cohort similarly reported significantly reduced risks of basal cell and squamous cell carcinoma, with a suggestive (though not statistically significant) reduction in melanoma as well. That study also found a small but significant reduction in internal malignancies.²⁶

The leading hypothesis is that the same overactive immune response that destroys melanocytes in vitiligo also provides heightened surveillance against melanocyte-derived cancers. Your immune system, in a sense, is too aggressive toward melanocytes, but that aggressiveness may carry a protective side effect. This does not mean people with vitiligo can skip sun protection on depigmented patches, which still lack melanin and burn easily, but it does complicate the picture of vitiligo as purely harmful.

Chemical and Occupational Triggers

Some cases of vitiligo appear to be triggered or accelerated by chemical exposures. A Tunisian case-control study found that occupational exposure to phenol and catechol derivatives, household chemical use, and repeated antibiotic use were each associated with a three- to four-fold increase in vitiligo risk.²⁷ This condition, sometimes called chemical leukoderma, is often under-diagnosed and has been reported as increasing in developing countries where unregulated household and industrial chemicals are widely used.²⁸ Chemical leukoderma can look identical to ordinary vitiligo, and both share genetic susceptibility factors, which is why the line between them is blurry even for dermatologists. The practical implication: if you develop white patches and work regularly with industrial chemicals, hair dyes, or rubber compounds, that occupational history is worth mentioning to your doctor.

Treatment Response Varies by Skin Type

Demographics influence not just who gets vitiligo but how well treatment works. Narrowband UVB phototherapy, one of the most widely used treatments, shows better repigmentation results on the face in patients with darker skin types (Fitzpatrick types III through V).²⁹ In studies of Asian children, generalized vitiligo responded better than segmental vitiligo across phototherapy modalities, with narrowband UVB producing the highest reported response rates.³⁰ The paradox here is that darker skin types, which suffer the most visible and psychologically distressing depigmentation, also tend to respond somewhat better to repigmentation therapies. That may be because the melanocyte reservoir in hair follicles, from which repigmentation often begins, is more robust in individuals with darker constitutive pigmentation.

Vitiligo in Animals

Vitiligo is not unique to humans. Dogs, cats, and horses all develop forms of the condition that mirror the human disease in many clinical features.³¹ The most striking example is in grey horses, where vitiligo-like depigmentation appears in 26% to 67% of grey-coated animals compared to only about 1% to 4% of non-grey horses.³² The genes implicated in equine vitiligo overlap with those involved in immune response and tumor metastasis, echoing the human observation that vitiligo and cancer immunity may be linked through shared pathways. Grey horses are already known to develop melanoma at high rates, and the same genetic variant that causes their progressive greying appears to simultaneously predispose them to both melanoma and vitiligo-like depigmentation. That makes them an unusually informative natural model for understanding how melanocyte-directed immunity can be both destructive and protective at the same time.

1
JEADV Clinical Practice. The global epidemiology of vitiligo: A systematic review and meta‐analysis of the incidence and prevalence
2
PubMed. Estimating the burden of vitiligo: a systematic review and modelling study
3
PLOS ONE. The Prevalence of Vitiligo: A Meta-Analysis
4
The Lancet. Global, regional, and national epidemiology of vitiligo: a systematic review and modelling analysis
5
PubMed Central. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA
6
PubMed Central. Epidemiology of Vitiligo – A Dual Population-Based Approach
7
PubMed Central. Prevalence of Vitiligo Among Adults in the United States
8
Frontiers in Medicine. Understanding vitiligo through the eyes of a typical patient in the U.S.
9
PubMed Central. Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims
10
PubMed Central. Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis
11
Journal of Investigative Dermatology. Familial Risk of Vitiligo among First-Degree Relatives and Spouses: A Population-Based Cohort Study in Korea
12
JAMA Dermatology. Pattern of Familial Aggregation of Vitiligo
13
PubMed Central. Impact of Consanguinity and Familial Aggregation on Vitiligo Epidemiology in Saudi Arabia: A Case-Control Study
14
Frontiers in Endocrinology. The Prevalence of Thyroid Disorders in Patients With Vitiligo: A Systematic Review and Meta-Analysis
15
PubMed. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea
16
PubMed Central. Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study
17
PubMed Central. Vitiligo is associated with an increased risk of cardiovascular diseases: a large-scale, propensity-matched, US-based retrospective study
18
PubMed Central. Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence
19
British Journal of Dermatology. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta‐analysis
20
Journal of Neurosciences in Rural Practice. Quality of life, depression, anxiety, stress symptoms, and its association with vitiligo extent and distribution: A cross-sectional study
21
PubMed Central. The mental health associations of vitiligo: UK population-based cohort study
22
PubMed Central. Impact on quality of life, health care access, and health care utilization of individuals with vitiligo: an analysis of the All of Us research program
23
PubMed. Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study
24
PubMed Central. Vitiligo: Epidemiology and Economic Impact
25
PubMed. Risk of Melanoma and Nonmelanoma Skin Cancer in People with Vitiligo: United Kingdom Population-Based Cohort Study
26
Scientific Reports. Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan
27
PubMed Central. Role of chemical exposure in the incidence of vitiligo: a case-control study in Tunisia
28
PubMed Central. Chemical Vitiligo: A Subset of Vitiligo
29
PubMed. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy
30
PubMed. Phototherapy for the treatment of vitiligo in Asian children
31
PubMed Central. Autoimmune diseases affecting skin melanocytes in dogs, cats and horses: vitiligo and the uveodermatological syndrome: a comprehensive review
32
PubMed Central. Equine vitiligo-like depigmentation in grey horses is related to genes involved in immune response and tumor metastasis